Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: Accounting for cardiovascular side effects and identifying new therapeutic applications

Molecular and Cellular Pharmacology

Volumn 2, Issue 1, 2010, Pages 15-19

  Brueggemann, Lioubov I ^a   Mani, Bharath K ^a   Mackie, Alexander R ^a   Cribbs, Leanne L ^a   Byron, Kenneth L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Blood pressure; Cardiovascular effects; Cyclooxygenase 2 inhibitors; Nonsteroidal anti inflammatory drugs; Vascular ion channels

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ION CHANNEL; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM CHANNEL KCNQ; ROFECOXIB;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHRONIC PAIN; DRUG CLASSIFICATION; DRUG MARKETING; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MEDICAL RESEARCH; MUSCLE RELAXATION; NONHUMAN; NOTE; PAIN; PRESCRIPTION; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

EID: 77953450650     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.03     Document Type: Note

References (35)

1. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol 2009;44:44-52.
2. Laine L. Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient. Gastroenterology 2001;120:594-606.
3. McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 2006;296:1633-44.
4. White WB, West CR, Borer JS, et al. Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Cardiology 2007;99:91-98.
5. Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-96.
6. Cho J, Cooke CE, Proveaux W. A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Am J Ther 2003;10:311-7.
7. Maljevic S, Wuttke TV, Lerche H. Nervous system Kv7 disorders: breakdown of a subthreshold brake. J Physiol 2008;586:1791-801.
8. Peroz D, Rodriguez N, Choveau F, et al. Kv7.1 (KCNQ1) properties and channelopathies. J Physiol 2008;586:1785-9.
9. Miceli F, Soldovieri MV, Martire M, et al. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 2008;8:65-74.
10. Yeung SY, Pucovsky V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007;151:758-70.
11. Mackie AR, Brueggemann LI, Henderson KK, et al. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 2008;325:475-83.
12. Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 2006;7:31.
13. Yeung SY, Greenwood IA. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 2005;146:585-95.
14. Joshi S, Sedivy V, Hodyc D, et al. KCNQ Modulators Reveal a Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle. J Pharmacol Exp Ther 2009;329:368-76.
15. Brueggemann LI, Moran CJ, Barakat JA, et al. Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 2007;292:H1352-H63.
16. Brueggemann LI, Mackie AR, Mani BK, et al. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 2009;76:1053-61.
17. Schönthal AH. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 2006;20:E21.
18. Hermann M, Shaw S, Kiss E, et al. Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension. Hypertension 2005;45:193-97.
19. Crowley RW, Medel R, Kassell NF, et al. New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discovery Today 2008;13:254-60.
20. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology 1998;50:1413-8.
21. Keyrouz SG, Diringer MN. Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care 2007;11:220.
22. Liu-Deryke X, Rhoney DH. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management. Pharmacotherapy 2006;26:182-203.
23. Park H-K, Lee S-H, Chu K, et al. Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci 2009;279:43-46.
24. Marnett LJ. The COXIB Experience: A Look in the Rear-View Mirror. Annu Rev Pharmacol Toxicol 2009;49:265-90.
25. Zhu J, Song X, Lin H-P, et al. Using Cyclooxygenase-2 Inhibitors as Molecular Platforms to Develop a New Class of Apoptosis-Inducing Agents. J Natl Cancer Inst 2002;94:1745-57.
26. Schönthal AH, Chen TC, Hofman FM, et al. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opinion on Investigational Drugs 2008;17:197-208.
27. Lang F, Foller M, Lang KS, et al. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol 2005;205:147-57.
28. Pardo LA, Contreras-Jurado C, Zientkowska M, et al. Role of Voltage-gated Potassium Channels in Cancer. J Membr Biol 2005;205:115-24.
29. + channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 2004;448:274-86.
30. Bock JM, Menon SG, Sinclair LL, et al. Celecoxib Toxicity Is Cell Cycle Phase Specific. Cancer Res 2007;67:3801-08.
31. Roura-Ferrer M, Solé L, Martínez-Mármol R, et al. Skeletal muscle Kv7 (KCNQ) channels in myoblast differentiation and proliferation. Biochem Biophys Res Commun 2008;369:1094-97.
32. Schroeder BC, Hechenberger M, Weinreich F, et al. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 2000;275:24089-95.
33. Lerche C, Scherer CR, Seebohm G, et al. Molecular Cloning and Functional Expression of KCNQ5, a Potassium Channel Subunit That May Contribute to Neuronal M-current Diversity. J Biol Chem 2000;275:22395-400.
34. Jensen HS, Callø K, Jespersen T, et al. The KCNQ5 potassium channel from mouse: A broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes. Molecular Brain Research 2005;139:52-62.
35. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.